HUBS LAUNCHED TO ENHANCE CLINICAL TRIAL CAPABILITY

NHS Digital, the national information and technology partner to the UK’s health and care system, is working with the University of Oxford, Microsoft and IBM to develop a new hub. This aims to revolutionise the way in which clinical trials are delivered. It will provide foundation services to determine whether a clinical trial is feasible, and to support better planning and delivery of clinical trials in the UK.

one of seven new hubs announced to enable research for health discoveries.

“NHS DigiTrial, the NHS Health Data Research Hub for Clinical Trials, is one of seven new hubs announced to enable research for health discoveries”

Led by Health Data Research UK, the hubs are the first of their kind in the world. It aims to improve the lives of people with debilitating conditions by making health data more accessible for research while maintaining strict controls around data security and privacy.

NHS DigiTrial, the NHS Health Data Research Hub for Clinical Trials, is

Diagnostics company acquired by Italian life science business

Blue Earth Diagnostics, a molecular imaging business helping to diagnose prostate cancer, has been sold by healthcare company Syncona to Bracco Imaging, part of the leading Italian multi-national healthcare company Bracco Group.

Blue Earth Diagnostics is now officially a subsidiary of Bracco Imaging. Led by its current leadership team it will retain the well-established Blue Earth Diagnostics name and its headquarters in Oxford, while maintaining a significant and operational presence across the US, based in Boston, Massachusetts.

Blue Earth Diagnostics employs approximately 100 people and was expected to generate revenues of 140 million dollars in the year to September 2019, primarily in the US.

The Nuffield Department of Population Health at the University of Oxford will provide clinical and trial leadership.